Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and corporate KOL panel at ESGO 2026 highlighted strong ACR-368 data in serous EC, a high unmet need

#ACRV Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/ACRV/acrivon-therap...

Most Searched, Thursday January 8, 2026 – Crystal Equity Research

Most searched small-cap stocks, Thu Jan 8th - #MLTX #RZLV #SHCO #RR #VTYX #ELME #ACRV #ACON #SERV #DNN #NEOG #TE #FLYX #TLRY #SG #RDW #IDR #HYMC #CRML #AEVA - More: crystalequityresearch.com/most-searche... #smallcap

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights Acrivon Therapeutics (Nasdaq: ACRV) reported third-quarter 2025 results and program updates on Nov 13, 2025. Key highlights include continued advancement of a registrational-intent Phase 2b trial of ACR-368 in recurrent high-grade endometrial cancer, an arm testing ultra-low dose gemcitabine without pre-treatment biopsy, and ongoing dosing in the Phase 1 dose-escalation study of ACR-2316 with reported tumor shrinkage and a confirmed partial response.Financials: Net loss $18.2M in Q3 2025 versus $22.4M year-ago; R&D $13.6M versus $18.9M; cash and investments $134.4M as of Sept 30, 2025, expected to fund operations into Q2 2027. The company also presented AP3/KaiSR platform and preclinical efficacy data at AACR-NCI-EORTC.

#ACRV Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/ACRV/acrivon-therap...

Acrivon's Cancer Drug Pipeline Advances with Tumor Response in Endometrial Cancer Trials Clinical-stage biotech reports positive data for two cancer drugs, with confirmed partial response in endometrial cancer. $147.6M cash runway extends to Q2 2027. Learn more.

#ACRV Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/ACRV/acrivon-therap...

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Acrivon Therapeutics (NASDAQ: ACRV) reported its Q1 2025 financial results and key developments. The company highlighted positive data for ACR-368 in endometrial cancer patients, showing a 35% confirmed overall response rate in OncoSignature-positive patients who had received prior anti-PD-1 and platinum-based chemotherapy. Their second clinical asset, ACR-2316, demonstrated promising results with ~25% tumor shrinkage observed in Phase 1 trials. The company appointed Dr. Mansoor Raza Mirza as CMO and reported $164.8 million in cash and equivalents, expected to fund operations into Q2 2027. Financial results showed a net loss of $19.7 million for Q1 2025, compared to $16.5 million in Q1 2024, with R&D expenses increasing to $15.4 million from $11.5 million year-over-year.

#ACRV Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/ACRV/acrivon-therap...

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results Acrivon Therapeutics (NASDAQ: ACRV) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company's ACR-368 showed promising results in endometrial cancer patients, achieving a 35% confirmed overall response rate in OncoSignature-positive patients who had previously progressed on anti-PD-1 and chemotherapy.Key clinical highlights include a 50% response rate in relapsed patients with duration of response exceeding 10 months, and 33% response rate in refractory patients. The Phase 1 trial of ACR-2316 is ahead of schedule, with initial clinical activity observed. The company has prioritized endometrial cancer development while deprioritizing ovarian and bladder cancer programs.Financial results show a net loss of $22.8 million for Q4 2024 and $80.6 million for the full year. With $184.6 million in cash and investments as of December 31, 2024, Acrivon expects to fund operations into 2027.

#ACRV Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/ACRV/acrivon-therap...

Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status Acrivon's ACR-368 OncoSignature assay receives FDA Breakthrough designation for endometrial cancer, showing 62.5% response rate in trials and targeting 30,000 annual U.S. cases.

#ACRV Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

www.stocktitan.net/news/ACRV/acrivon-therap...